Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31140836 | 1.00 | CTSC (0.33) | CTSCCYP11B2USP2PGRCYP2D6 | |
| SCHEMBL26496339 | 0.92 | CTSC (0.32) | CTSCCYP11B2USP2PGR | |
| SCHEMBL25619716 | 0.85 | CYP11B2 (0.36) | CTSCCYP11B2PGR | |
| SCHEMBL31561370 | 0.83 | SLC6A3 (0.31) | — | |
| SCHEMBL25901443 | 0.83 | SLC6A3 (0.31) | — | |
| SCHEMBL31140819 | 0.82 | MAOB (0.35) | TSHR | |
| SCHEMBL25317458 | 0.82 | MAOB (0.35) | TSHR | |
| SCHEMBL25318459 | 0.80 | — | — | |
| SCHEMBL31140818 | 0.80 | — | — | |
| SCHEMBL26496683 | 0.78 | CYP11B2 (0.33) | CYP11B2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4469157-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118696035-A | Spiropiperidyl derivatives as complement factor B inhibitors and their use | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139534-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115572-A1 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, C1QBP, CFH | CTSC 574/4885CYP11B2 1676/4885USP2 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.